Navigation Links
AtriCure to Present at Roth Capital Partners 2007 New York Conference
Date:8/31/2007

WEST CHESTER, Ohio, Aug. 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital Partners 2007 New York Conference at The Westin New York at Times Square on Thursday, September 6th, at 10:00 a.m. ET.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative cardiac surgical devices designed to create precise lesions, or scars, in cardiac and soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) bipolar ablation clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system for the ablation, or destruction, of cardiac and soft tissues in cardiac and general surgical procedures but has not yet cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar pen for the ablation of cardiac tissue
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...cus on Millions of Children Still in Danger, NEW ...CEF and The,Advertising Council today announced a ...national public service announcements (PSAs) filme...cole Ritchie, Joel Madden, David,Duchovny, Tea Leo...of the,Myanmar cyclone. The Ad Council is distribu...
(Date:5/16/2008)...RNewswire/ -- ExamForce announced today the,hiring...ment Sales Manager.,Mongeon formerly headed up the...where he oversaw government sales and marketing in... security certifications in the IT,industry., Mon...left (ISC)2,Americas to spend more time with his t...
(Date:5/16/2008)...ly disseminated to community physicians, audit fin...- Partnerships between major academic cancer cente...ve way to spread cancer treatment advances, say re...ia. , Most new cancer treatments are created at...ovided at community hospitals, noted the researche...
(Date:5/16/2008).../PRNewswire-USNewswire/ -- Karin Weisburgh,senior...t publisher of,Consumer Reports magazine, was name... at CU,s Yonkers headquarters today., Ms. Weisbur...les up in,the winter and rides in shirt sleeves in...ong Quaker Ridge in New Rochelle, down Mill Road i...
Breaking Medicine News(10 mins):Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3
...s reported that an 8-year decline in the smoking r... to its halt at 21% in the last 2 years//. Accord...ease Control and Prevention, a lack of drop in smo...e 2002 is represented by the plateaus in smoking p...
...s in Jaipur, flower therapy is becoming the most s...ople enhance their beauty are parlours// and clini...roblems or under eye dark circles, flower therapy ..."We get 7 to 10 customers every day," says Neerja,...
... in St.Hyacinthe, 65 km south east of Montreal h...d diarrhoea which is still to be contained// . 22 ... well have been affected. The infection has been ...ince July and is believed have been responsible fo...
...l that more than half the population in New South ...he 30,000 people who were interviewed// this year...lects that there is almost 10%increase in obesity ...s population survey also brings to light that most...
Other Medicine News:Health News:Drop in smoking rate stalls 2
(Date:5/15/2008)...flects depth and breadth of, collaboration with i...or diverse forms of cancer ...R), the leading IV, bisphosphonate, on relapse rat...our oral sessions to feature RAD001, first oral on...first results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...May 15 /- Cerenis,Therapeutics SA (Ce...veloping HDL-related compounds for the treatment o...ounced that it has completed a Phase I,clinical tr... candidates.,CER-002 is a peroxisome proliferator-...n development for the treatment of cardiovascular,...
(Date:5/15/2008)...iplatelet Therapy that, Combined, with Aspirin, Ca...Iscover and Aspirin, According to a New Report.../- Decision Resources, one of the,wor...aceutical and,healthcare issues, finds that Daiich... patient compared to Sanofi-Aventis/Bristol Myers ...
(Date:5/15/2008)... Omega 3 fatty acids bound to,phospholipids deserv...alternative and may have beneficial effect on impu...udy reveals. While several studies have reported,b...nch researchers have,hypothesized that Vectomega(R...control., These research findings have led to the...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 1Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 2Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 16532 3Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference 16530 1Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference 16530 2Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 1Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 2Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 3Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 4Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 5Cardinal Health Awards 241 Million to Fund Patient Safety Initiatives 16528 6Amnis Announces Release of Powerful New Image Data Analysis Software 4526 1Amnis Announces Release of Powerful New Image Data Analysis Software 4526 2
...ht Change Reported Unlike What Is Commonly Seen In...re-FirstCall/ -- Novo Nordisk,today announced resu...afety and efficacy of insulin Levemir(R) (insulin ...pe 2 diabetes were able,to adjust their own dosage...ugar, comparable to dosing adjusted by their prima...
...SINESS WIRE)--Jun 23, 2007 - Late breaking data,pr... 67th Annual,Scientific Sessions showed that, when...A(TM) (sitagliptin) in combination with,metformin ...generally well tolerated over 54 weeks in patients...vestigational studies,presented also showed that J...
Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet.
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm.
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Medicine Products: